Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Phone617-679-2000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$13.45 billion
Profitability
Miscellaneous
Employees7,800
Next Earnings Date10/22/2019 (Estimated)
OptionableOptionable
Biogen (NASDAQ:BIIB) Frequently Asked Questions
What is Biogen's stock symbol?
Biogen trades on the NASDAQ under the ticker symbol "BIIB."
How were Biogen's earnings last quarter?
Biogen Inc (NASDAQ:BIIB) announced its quarterly earnings data on Tuesday, July, 23rd. The biotechnology company reported $9.15 EPS for the quarter, topping the Zacks' consensus estimate of $7.58 by $1.57. The biotechnology company earned $3.62 billion during the quarter, compared to the consensus estimate of $3.48 billion. Biogen had a return on equity of 44.89% and a net margin of 37.62%. The company's quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter last year, the company earned $5.80 EPS. View Biogen's Earnings History.
When is Biogen's next earnings date?
What guidance has Biogen issued on next quarter's earnings?
Biogen updated its FY19 earnings guidance on Tuesday, July, 23rd. The company provided earnings per share (EPS) guidance of $31.50-32.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $29.76. The company issued revenue guidance of $14-14.2 billion, compared to the consensus revenue estimate of $13.96 billion.
What price target have analysts set for BIIB?
30 brokerages have issued 12 month price objectives for Biogen's stock. Their forecasts range from $198.00 to $400.00. On average, they expect Biogen's share price to reach $270.00 in the next twelve months. This suggests a possible upside of 13.1% from the stock's current price. View Analyst Price Targets for Biogen.
What is the consensus analysts' recommendation for Biogen?
30 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 2 sell ratings, 23 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Biogen.
What are Wall Street analysts saying about Biogen stock?
Here are some recent quotes from research analysts about Biogen stock:
- 1. Cantor Fitzgerald analysts commented, ": Reiterate Neutral rating and $250 price target. Yesterday Novartis (NVS, NC) announced FDA approval of its oral S1P1 Mayzent (siponimod) in secondary progressive multiple sclerosis (SPMS), relapsing-remitting MS (RRMS), and clinically isolated syndrome using a priority voucher. We think this broad label is somewhat unexpected given that the pivotal study and regulatory filings were for SPMS patients, and a negative headline for competitors such as Biogen and possibly Celgene CELG, OW). With competitive efficacy and a cleaner label vs. NVS’ first gen S1P1 Gilenya, we think the key question is if and how quickly Mayzent can take share in RRMS post launch in early 2Q." (3/27/2019)
- 2. HC Wainwright analysts commented, "Our PT of $363/share is based on a discounted cash flow analysis using a 10% discount rate and 2% growth rate, in line with the expected discount and growth parameters of a commercial multiproduct biotechnology company. Risks to our investment thesis and target price include: (1) failure in clinical studies; (2) failure to secure regulatory approval; and (3) a smaller than anticipated commercial opportunity due to market size, competition, and/or pricing." (2/19/2019)
Has Biogen been receiving favorable news coverage?
Media coverage about BIIB stock has trended negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Biogen earned a news sentiment score of -2.9 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for Biogen.
Are investors shorting Biogen?
Biogen saw a increase in short interest in August. As of August 15th, there was short interest totalling 4,118,800 shares, an increase of 8.7% from the July 15th total of 3,788,600 shares. Based on an average daily volume of 1,570,000 shares, the days-to-cover ratio is currently 2.6 days. Approximately 2.1% of the company's stock are sold short. View Biogen's Current Options Chain.
Who are some of Biogen's key competitors?
Some companies that are related to Biogen include Amgen (AMGN), Gilead Sciences (GILD), NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Neurocrine Biosciences (NBIX), Qiagen (QGEN), BIO-TECHNE (TECH), Moderna (MRNA), bluebird bio (BLUE), Adaptive Biotechnologies (ADPT), argenx (ARGX), Repligen (RGEN), China Biologic Products (CBPO), Spark Therapeutics (ONCE) and Allogene Therapeutics (ALLO).
What other stocks do shareholders of Biogen own?
Who are Biogen's key executives?
Biogen's management team includes the folowing people:
- Mr. Michel Vounatsos, CEO & Director (Age 57)
- Mr. Jeffrey D. Capello, Exec. VP & CFO (Age 54)
- Ms. Susan H. Alexander, Exec. VP, Chief Legal Officer & Sec. (Age 62)
- Dr. Michael D. Ehlers, Exec. VP and Head of R&D (Age 50)
- Dr. Paul F. McKenzie, Exec. VP of Pharmaceutical Operations & Technology (Age 53)
Who are Biogen's major shareholders?
Biogen's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.68%), BlackRock Inc. (8.68%), Vanguard Group Inc. (8.03%), Primecap Management Co. CA (7.89%), AQR Capital Management LLC (2.06%) and Invesco Ltd. (1.62%). Company insiders that own Biogen stock include Alexander J Denner, Alfred Sandrock, Michael D Ehlers, Michel Vounatsos and Robert W Pangia. View Institutional Ownership Trends for Biogen.
Which major investors are selling Biogen stock?
BIIB stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, AQR Capital Management LLC, Banco Santander S.A., BlackRock Inc., BlackRock Inc., Invesco Ltd., Westfield Capital Management Co. LP and Vanguard Group Inc.. Company insiders that have sold Biogen company stock in the last year include Michael D Ehlers and Robert W Pangia. View Insider Buying and Selling for Biogen.
Which major investors are buying Biogen stock?
BIIB stock was purchased by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Renaissance Technologies LLC, Boston Partners, Parnassus Investments CA, Jacobs Levy Equity Management Inc., First Trust Advisors LP, Man Group plc and Cibc World Markets Corp. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner and Michel Vounatsos. View Insider Buying and Selling for Biogen.
How do I buy shares of Biogen?
Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Biogen's stock price today?
One share of BIIB stock can currently be purchased for approximately $238.79.
How big of a company is Biogen?
Biogen has a market capitalization of $44.04 billion and generates $13.45 billion in revenue each year. The biotechnology company earns $4.43 billion in net income (profit) each year or $26.20 on an earnings per share basis. Biogen employs 7,800 workers across the globe.View Additional Information About Biogen.
What is Biogen's official website?
How can I contact Biogen?
Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000 or via email at [email protected]
MarketBeat Community Rating for Biogen (NASDAQ BIIB)
MarketBeat's community ratings are surveys of what our community members think about Biogen and other stocks. Vote "Outperform" if you believe BIIB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIIB will underperform the S&P 500 over the long term. You may vote once every thirty days.
